HC Wainwright Issues Positive Outlook for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – HC Wainwright upped their Q3 2026 earnings estimates for CervoMed in a note issued to investors on Wednesday, August 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.48) per share for the quarter, up from their prior forecast of ($0.60). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($2.32) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.90) EPS.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.22. CervoMed had a negative return on equity of 166.00% and a negative net margin of 672.80%.

Other analysts have also recently issued reports about the stock. Weiss Ratings cut shares of CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Chardan Capital upgraded CervoMed to a “strong-buy” rating in a report on Monday, August 3rd. Roth Capital set a $9.00 price target on shares of CervoMed in a research report on Monday, May 18th. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of CervoMed in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

CervoMed Stock Performance

CRVO opened at $2.93 on Friday. The firm has a market cap of $44.30 million, a price-to-earnings ratio of -0.91 and a beta of -0.63. The firm’s 50-day simple moving average is $3.12 and its 200-day simple moving average is $3.75. CervoMed has a twelve month low of $2.13 and a twelve month high of $11.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers increased its stake in CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares in the last quarter. State Street Corp boosted its position in shares of CervoMed by 11.4% during the fourth quarter. State Street Corp now owns 20,527 shares of the company’s stock worth $162,000 after purchasing an additional 2,100 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of CervoMed by 1.0% during the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares in the last quarter. Citizens Financial Group Inc. RI grew its holdings in shares of CervoMed by 23.0% in the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock valued at $296,000 after buying an additional 7,000 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of CervoMed in the 4th quarter valued at $81,000. Institutional investors own 25.15% of the company’s stock.

Insider Transactions at CervoMed

In related news, Director Joshua S. Boger bought 955,414 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $3.14 per share, for a total transaction of $2,999,999.96. Following the transaction, the director owned 1,795,865 shares of the company’s stock, valued at $5,639,016.10. This represents a 113.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 35.80% of the company’s stock.

CervoMed News Roundup

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: HC Wainwright raised multiple EPS forecasts and reaffirmed its Buy rating. The firm improved its estimates for CervoMed’s Q3 2026 EPS to $(0.48) from $(0.60), Q4 2026 to $(0.48) from $(0.59), and full-year 2026 to $(2.32) from $(2.70). It also raised its Q1 2027 estimate to $(0.46), Q2 2027 to $(0.41), and FY2027 to $(1.90) from $(1.99). These revisions imply analysts expect narrower losses than previously forecast. CervoMed analyst estimates
• Positive Sentiment: Brookline Capital Markets also reduced its projected losses. The firm raised its Q3 2026 EPS estimate to $(0.73) from $(1.04), Q4 2026 to $(0.75) from $(1.55), and FY2026 to $(2.97) from $(4.34). The revisions provide additional evidence of improving near-term earnings expectations, although Brookline’s outlook remains less optimistic than HC Wainwright’s. CervoMed analyst estimates
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating, reinforcing the favorable analyst view of CervoMed’s prospects. HC Wainwright Reaffirms Buy Rating for CervoMed
• Negative Sentiment: CervoMed is still expected to report substantial losses: the consensus forecast calls for approximately $(2.50) in EPS for the current year. The company also has a negative net margin and return on equity, so the improved estimates represent narrower losses rather than profitability.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.